<b>Aim:</b> To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer.<b> Materials & methods:</b> We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of blood biomarkers.
<b>Aim:</b> To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer.<b> Materials & methods:</b> We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of blood biomarkers.
<b>Aim:</b> To evaluate the value of pretreatment blood biomarkers in predicting pathologic responses to neoadjuvant chemoradiotherapy (neo-CRT) in patients with locally advanced rectal cancer.<b> Materials & methods:</b> We conducted logistic regression analysis and receiver operating characteristic to assess the predictive value of blood biomarkers.
<b>Conclusion:</b> DUOX2 may play a pivotal role in carcinogenesis, tumor progression and response to neoadjuvant CCRT in rectal cancers, and serve as a novel prognostic biomarker.
<b>Conclusion:</b> Lower LMR and higher CEA, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before treatment could predict poorer pathologic response to neo-CRT in patients with locally advanced rectal cancer.
<b>Conclusions:</b> The current study indicates that genetic variations within the PI3K/ PTEN/AKT/mTOR signaling pathway are associated with the clinical outcomes of LARC patients undergoing preoperative CRT followed by radical surgery.
<b>Conclusions:</b> The current study indicates that genetic variations within the PI3K/ PTEN/AKT/mTOR signaling pathway are associated with the clinical outcomes of LARC patients undergoing preoperative CRT followed by radical surgery.
<b>Methods:</b> Through data mining from a published transcriptome of rectal cancers (GSE35452), we identified upregulation of <i>TCN1</i> gene as the most significantly predicted poor response to CCRT among ion transport-related genes (GO:0006811).
55 patients with locally advanced rectal carcinoma (cT3-4, N0, M0 or cT2-4,N+, M0) were treated with capecitabine 825 mg/m2 twice a day and pelvic radiotherapy 1,8 Gy daily up to cumulative dose of 45 Gy, boosting up to 50,4 Gy.
Rectal cancer risks were associated with the highest TTHM levels (HR<sub>Q5vsQ1</sub> = 1.71, CI = 1.00-2.92; p<sub>trend</sub> = 0.22) but not with years >1/2-MCL.
Rectal cancer risks were associated with the highest TTHM levels (HR<sub>Q5vsQ1</sub> = 1.71, CI = 1.00-2.92; p<sub>trend</sub> = 0.22) but not with years >1/2-MCL.
WNT3 was significantly up-regulated in a case of primary breast cancer and in a case of primary rectal cancer among various types of human primary cancers.
VKORC1 Haplotype A) and somatic mutations (e.g. epidermal growth factor receptor), along with the introduction of FDA approved pharmacogenetic tests (UGT1A1*28) and the initiation of a genotype-guided clinical trial for cancer therapy (TYMS TSER in rectal cancer) have provided the first steps towards the integration of pharmacogenomics into clinical practice.